Boston Institute of Biotechnology’s groundbreaking 30,000L bioreactor made of stainless steel and Grand-CHO platform are reshaping biologics manufacturing, driving efficiency and lowering production costs.
The Boston Institute of Biotechnology, LLC (BIB) has announced that its CEO has been honoured with the prestigious 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan. This award recognises BIB’s revolutionary innovations in biologics manufacturing, including the world’s first 30,000L stainless steel bioreactor and its advanced Grand-CHO platform.
As the demand for commercial-scale biologics continues to rise, traditional small-scale bioreactors have struggled to meet global production capacity needs. BIB’s cutting-edge 30,000L bioreactor addresses these challenges, offering unprecedented scalability and reducing production costs to as low as $10 per gram—dramatically lower than the industry average of hundreds of dollars per gram.
BIB’s bioreactor, boasting a total volume of over 40,000L, marks a significant leap forward in biomanufacturing, offering faster time-to-market for new drugs while slashing operational costs. The company has recently completed Phase 3 of its expansive Contract Development and Manufacturing Organisation (CDMO) facility, adding over 200,000 litres of production capacity across a 123,700 square metre site.
With an executive team averaging over 20 years of experience, BIB has led more than 162 successful projects in the global biopharmaceutical space. The firm’s PanFlex-Engineering system allows for faster, cost-effective development of manufacturing sites, meeting stringent international quality standards from the FDA, EMA, PMDA and China NMPA.
BIB continues to push the boundaries of biologics manufacturing, accelerating access to innovative therapies for patients worldwide.
Source: PRNewswire.com
